Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGF23 | Q9GZV9 | 3/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | GSR | P00390 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3378277 | 0.98 | FGF23 (0.53) | FGF23PTGS2SLC6A3CFTRGOPC | |
| SCHEMBL1700335 | 0.80 | SLC6A3 (0.46) | FGF23PTGS2SLC6A3SLC6A2ALDH1A1 | |
| SCHEMBL16439215 | 0.80 | MAPK14 (0.47) | FGF23PTGS2SLC6A3ALDH1A1KDM4E | |
| SCHEMBL17460574 | 0.80 | PTGS2 (0.47) | FGF23PTGS2SLC6A3ALDH1A1CYP2A6 | |
| SCHEMBL1957404 | 0.79 | SLC6A3 (0.47) | FGF23PTGS2SLC6A3SLC6A2ALDH1A1 | |
| SCHEMBL1957401 | 0.79 | SLC6A3 (0.47) | FGF23PTGS2SLC6A3SLC6A2ALDH1A1 | |
| SCHEMBL1956409 | 0.79 | SLC6A3 (0.47) | FGF23PTGS2SLC6A3SLC6A2ALDH1A1 | |
| SCHEMBL15171504 | 0.78 | CHRNB4 (0.49) | FGF23SLC6A3SLC6A2CHRNB4CHRNA3 | |
| SCHEMBL11844479 | 0.77 | SLC6A3 (0.31) | SLC6A3 | |
| SCHEMBL8653245 | 0.77 | PTGS2 (0.54) | FGF23PTGS2SLC6A3CFTRGOPC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210346405-A1 | BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED | 2021-11-11 | — | — | US | disclosed |
| WO-2021222174-A1 | BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2021-11-04 | — | — | WO | disclosed |
| US-11161823-B2 | Anticancer 1,3-dioxane-4,6-dione derivatives and method of combinatorial synthesis thereof | NATIONAL GUARD HEALTH AFFAIRS (SA) | 2021-11-02 | — | — | US | disclosed |
| US-20200290975-A1 | ANTICANCER 1,3-DIOXANE-4,6-DIONE DERIVATIVES AND METHOD OF COMBINATORIAL SYNTHESIS THEREOF | NATIONAL GUARD HEALTH AFFAIRS (SA) | 2020-09-17 | — | — | US | disclosed |
| EP-3172185-B1 | SUBSTITUTED PHENYL ALKANOIC ACID COMPOUNDS AS GPR120 AGONISTS AND USES THEREOF | PIRAMAL ENTPR LTD (IN) | 2020-03-04 | — | — | EP | disclosed |
| US-10273230-B2 | Substituted phenyl alkanoic acid compounds as GPR120 agonists and uses thereof | Piramal Enterprises Limited (IN) | 2019-04-30 | — | — | US | disclosed |
| US-9745240-B2 | Metal free process for allylic oxidation | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2017-08-29 | — | — | US | disclosed |
| US-9745240-B2 | Metal free process for allylic oxidation | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2017-08-29 | — | — | US | disclosed |
| US-20170210731-A1 | SUBSTITUTED PHENYL ALKANOIC ACID COMPOUNDS AS GPR120 AGONISTS AND USES THEREOF | Piramal Enterprises Limited (IN) | 2017-07-27 | — | — | US | disclosed |
| EP-3172185-A2 | SUBSTITUTED PHENYL ALKANOIC ACID COMPOUNDS AS GPR120 AGONISTS AND USES THEREOF | Piramal Enterprises Limited (IN) | 2017-05-31 | — | — | EP | disclosed |
| US-20160159717-A1 | NOVEL METAL FREE PROCESS FOR ALLYLIC OXIDATION | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2016-06-09 | — | — | US | disclosed |
| US-20160159717-A1 | NOVEL METAL FREE PROCESS FOR ALLYLIC OXIDATION | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2016-06-09 | — | — | US | disclosed |
| WO-2016012965-A2 | SUBSTITUTED PHENYL ALKANOIC ACID COMPOUNDS AS GPR120 AGONISTS AND USES THEREOF | Piramal Enterprises Limited (IN) | 2016-01-28 | — | — | WO | disclosed |
| WO-2015015511-A1 | NOVEL METAL FREE PROCESS FOR ALLYLIC OXIDATION | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346405-A1 | BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS | BCL2, BCL2L2, BCL2L1 | FGF23 2301/4885PTGS2 431/4885SLC6A3 4730/4885 |
| US-11161823-B2 | Anticancer 1,3-dioxane-4,6-dione derivatives and method of combinatorial synthesis thereof | PDK1, PDHA1, PDHA2 | FGF23 2770/4885PTGS2 2444/4885SLC6A3 3805/4885 |
| US-20160159717-A1 | NOVEL METAL FREE PROCESS FOR ALLYLIC OXIDATION | NFE2L2, PPOX, NOX4 | FGF23 4488/4885PTGS2 76/4885SLC6A3 3198/4885 |
| US-20170210731-A1 | SUBSTITUTED PHENYL ALKANOIC ACID COMPOUNDS AS GPR120 AGONISTS AND USES THEREOF | FFAR1, FFAR3, GPR55 | FGF23 1673/4885PTGS2 679/4885SLC6A3 728/4885 |
| US-10273230-B2 | Substituted phenyl alkanoic acid compounds as GPR120 agonists and uses thereof | FFAR1, FFAR3, GPR55 | FGF23 1673/4885PTGS2 679/4885SLC6A3 728/4885 |
| US-20200290975-A1 | ANTICANCER 1,3-DIOXANE-4,6-DIONE DERIVATIVES AND METHOD OF COMBINATORIAL SYNTHESIS THEREOF | PDK1, PDHA1, PDHA2 | FGF23 2770/4885PTGS2 2444/4885SLC6A3 3805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.